Reply

Marc G. Ghany; Wendy C. King; Mauricio Lisker-Melman; Anna S.F. Lok; Norah Terrault; Harry L.A. Janssen; Mandana Khalili; Raymond T. Chung; William M. Lee; Daryl T.Y. Lau; Gavin A. Cloherty; Richard K. Sterling

doi:10.1002/hep.32251

Reply

Marc G. Ghany, Wendy C. King, Mauricio Lisker-Melman, Anna S.F. Lok, Norah Terrault, Harry L.A. Janssen, Mandana Khalili, Raymond T. Chung, William M. Lee, Daryl T.Y. Lau, Gavin A. Cloherty, Richard K. Sterling

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	761-763
Number of pages	3
Journal	Hepatology
Volume	75
Issue number	3
DOIs	https://doi.org/10.1002/hep.32251
State	Published - Mar 2022

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.32251

Cite this

@article{8a7d799f44a241c3a1b394bbaba145a4,

title = "Reply",

author = "Ghany, {Marc G.} and King, {Wendy C.} and Mauricio Lisker-Melman and Lok, {Anna S.F.} and Norah Terrault and Janssen, {Harry L.A.} and Mandana Khalili and Chung, {Raymond T.} and Lee, {William M.} and Lau, {Daryl T.Y.} and Cloherty, {Gavin A.} and Sterling, {Richard K.}",

note = "Funding Information: The authors acknowledge the use of Hepatitis B Research Network (HBRN) samples and data as the sole contribution of the HBRN. The HBRN was funded as a Cooperative Agreement between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the following investigators: Lewis R. Roberts, MB, ChB, PhD (U01-DK082843), Anna Suk-Fong Lok, MD (U01-DK082863), Steven H. Belle, PhD, MScHyg (U01-DK082864), Kyong-Mi Chang, MD (U01-DK082866), Michael W. Fried, MD (U01-DK082867), Adrian M. Di Bisceglie, MD (U01-DK082871), William M. Lee, MD (U01-DK082872), Harry L. A. Janssen, MD, PhD (U01-DK082874), Daryl T-Y Lau, MD, MPH (U01-DK082919), Richard K. Sterling, MD, MSc (U01-DK082923), Steven-Huy B. Han, MD (U01-DK082927), Robert C. Carithers, MD (U01-DK082943), and Mandana Khalili, MD (U01-DK082944); an interagency agreement with NIDDK: Lilia M. Ganova-Raeva, PhD (A-DK-3002-001); and support from the intramural program, NIDDK, National Institues of Health (NIH): Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong-Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306, NIH Public Health Service Research Grant M01-RR00040), Richard K. Sterling, MD, MSc (UL1TR000058, National Center for Advancing Translational Sciences, NIH), Mandana Khalili, MD, MAS (CTSA UL1TR000004), Michael W. Fried, MD (CTSA UL1TR001111), and Anna Suk-Fong Lok (CTSA UL1RR024986 and U54TR001959.) Additional support was provided by Gilead Sciences, Inc., and Roche Molecular Systems via a CRADA through the NIDDK. Funding Information: Dr. Lau consults for Abbott and advises Gilead. Dr. King received grants from AbbVie. Dr. Lisker‐Melman is on the speakers{\textquoteright} bureau for AbbVie and Gilead. Dr. Terrault consults for EXIGO, ENYO, PPD Pharma, and Entourage. She received grants from Gilead, Genentech, and Roche. Dr. Janssen consults and received grants from Gilead, GlaxoSmithKline, Janssen, Roche, and Vir. He consults for Aligos, Antios, Arbutus, Eiger, Viroclinics, and VBI Vaccines. He received grants from AbbVie. Dr. Khalili consults and received grants from Gilead. She received grants from AbbVie. Dr. Chung received grants from Gilead, Bristol‐Myers Squibb, Boehringer Ingelheim, Janssen, Merck, and Roche. Dr. Lee consults for Forma, SeaGen, Karuna, and Cortexyme. He received grants from Merck, Bristol‐Myers Squibb, Intercept, Aurora, Novo Nordisk, Cumberland, and Meridian. Dr. Cloherty is employed and owns stock in Abbott. Dr. Sterling is on the data security monitoring board for AskBio and Pfizer. He received grants from Roche, Abbott, AbbVie, and Gilead. Funding Information: The authors acknowledge the use of Hepatitis B Research Network (HBRN) samples and data as the sole contribution of the HBRN. The HBRN was funded as a Cooperative Agreement between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the following investigators: Lewis R. Roberts, MB, ChB, PhD (U01‐DK082843), Anna Suk‐Fong Lok, MD (U01‐DK082863), Steven H. Belle, PhD, MScHyg (U01‐DK082864), Kyong‐Mi Chang, MD (U01‐DK082866), Michael W. Fried, MD (U01‐DK082867), Adrian M. Di Bisceglie, MD (U01‐DK082871), William M. Lee, MD (U01‐DK082872), Harry L. A. Janssen, MD, PhD (U01‐DK082874), Daryl T‐Y Lau, MD, MPH (U01‐DK082919), Richard K. Sterling, MD, MSc (U01‐DK082923), Steven‐Huy B. Han, MD (U01‐DK082927), Robert C. Carithers, MD (U01‐DK082943), and Mandana Khalili, MD (U01‐DK082944); an interagency agreement with NIDDK: Lilia M. Ganova‐Raeva, PhD (A‐DK‐3002‐001); and support from the intramural program, NIDDK, National Institues of Health (NIH): Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong‐Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306, NIH Public Health Service Research Grant M01‐RR00040), Richard K. Sterling, MD, MSc (UL1TR000058, National Center for Advancing Translational Sciences, NIH), Mandana Khalili, MD, MAS (CTSA UL1TR000004), Michael W. Fried, MD (CTSA UL1TR001111), and Anna Suk‐Fong Lok (CTSA UL1RR024986 and U54TR001959.) Additional support was provided by Gilead Sciences, Inc., and Roche Molecular Systems via a CRADA through the NIDDK. ",

year = "2022",

month = mar,

doi = "10.1002/hep.32251",

language = "English (US)",

volume = "75",

pages = "761--763",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Reply

AU - Ghany, Marc G.

AU - King, Wendy C.

AU - Lisker-Melman, Mauricio

AU - Lok, Anna S.F.

AU - Terrault, Norah

AU - Janssen, Harry L.A.

AU - Khalili, Mandana

AU - Chung, Raymond T.

AU - Lee, William M.

AU - Lau, Daryl T.Y.

AU - Cloherty, Gavin A.

AU - Sterling, Richard K.

N1 - Funding Information: The authors acknowledge the use of Hepatitis B Research Network (HBRN) samples and data as the sole contribution of the HBRN. The HBRN was funded as a Cooperative Agreement between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the following investigators: Lewis R. Roberts, MB, ChB, PhD (U01-DK082843), Anna Suk-Fong Lok, MD (U01-DK082863), Steven H. Belle, PhD, MScHyg (U01-DK082864), Kyong-Mi Chang, MD (U01-DK082866), Michael W. Fried, MD (U01-DK082867), Adrian M. Di Bisceglie, MD (U01-DK082871), William M. Lee, MD (U01-DK082872), Harry L. A. Janssen, MD, PhD (U01-DK082874), Daryl T-Y Lau, MD, MPH (U01-DK082919), Richard K. Sterling, MD, MSc (U01-DK082923), Steven-Huy B. Han, MD (U01-DK082927), Robert C. Carithers, MD (U01-DK082943), and Mandana Khalili, MD (U01-DK082944); an interagency agreement with NIDDK: Lilia M. Ganova-Raeva, PhD (A-DK-3002-001); and support from the intramural program, NIDDK, National Institues of Health (NIH): Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong-Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306, NIH Public Health Service Research Grant M01-RR00040), Richard K. Sterling, MD, MSc (UL1TR000058, National Center for Advancing Translational Sciences, NIH), Mandana Khalili, MD, MAS (CTSA UL1TR000004), Michael W. Fried, MD (CTSA UL1TR001111), and Anna Suk-Fong Lok (CTSA UL1RR024986 and U54TR001959.) Additional support was provided by Gilead Sciences, Inc., and Roche Molecular Systems via a CRADA through the NIDDK. Funding Information: Dr. Lau consults for Abbott and advises Gilead. Dr. King received grants from AbbVie. Dr. Lisker‐Melman is on the speakers’ bureau for AbbVie and Gilead. Dr. Terrault consults for EXIGO, ENYO, PPD Pharma, and Entourage. She received grants from Gilead, Genentech, and Roche. Dr. Janssen consults and received grants from Gilead, GlaxoSmithKline, Janssen, Roche, and Vir. He consults for Aligos, Antios, Arbutus, Eiger, Viroclinics, and VBI Vaccines. He received grants from AbbVie. Dr. Khalili consults and received grants from Gilead. She received grants from AbbVie. Dr. Chung received grants from Gilead, Bristol‐Myers Squibb, Boehringer Ingelheim, Janssen, Merck, and Roche. Dr. Lee consults for Forma, SeaGen, Karuna, and Cortexyme. He received grants from Merck, Bristol‐Myers Squibb, Intercept, Aurora, Novo Nordisk, Cumberland, and Meridian. Dr. Cloherty is employed and owns stock in Abbott. Dr. Sterling is on the data security monitoring board for AskBio and Pfizer. He received grants from Roche, Abbott, AbbVie, and Gilead. Funding Information: The authors acknowledge the use of Hepatitis B Research Network (HBRN) samples and data as the sole contribution of the HBRN. The HBRN was funded as a Cooperative Agreement between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the following investigators: Lewis R. Roberts, MB, ChB, PhD (U01‐DK082843), Anna Suk‐Fong Lok, MD (U01‐DK082863), Steven H. Belle, PhD, MScHyg (U01‐DK082864), Kyong‐Mi Chang, MD (U01‐DK082866), Michael W. Fried, MD (U01‐DK082867), Adrian M. Di Bisceglie, MD (U01‐DK082871), William M. Lee, MD (U01‐DK082872), Harry L. A. Janssen, MD, PhD (U01‐DK082874), Daryl T‐Y Lau, MD, MPH (U01‐DK082919), Richard K. Sterling, MD, MSc (U01‐DK082923), Steven‐Huy B. Han, MD (U01‐DK082927), Robert C. Carithers, MD (U01‐DK082943), and Mandana Khalili, MD (U01‐DK082944); an interagency agreement with NIDDK: Lilia M. Ganova‐Raeva, PhD (A‐DK‐3002‐001); and support from the intramural program, NIDDK, National Institues of Health (NIH): Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong‐Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306, NIH Public Health Service Research Grant M01‐RR00040), Richard K. Sterling, MD, MSc (UL1TR000058, National Center for Advancing Translational Sciences, NIH), Mandana Khalili, MD, MAS (CTSA UL1TR000004), Michael W. Fried, MD (CTSA UL1TR001111), and Anna Suk‐Fong Lok (CTSA UL1RR024986 and U54TR001959.) Additional support was provided by Gilead Sciences, Inc., and Roche Molecular Systems via a CRADA through the NIDDK.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85121444001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121444001&partnerID=8YFLogxK

U2 - 10.1002/hep.32251

DO - 10.1002/hep.32251

M3 - Letter

C2 - 34800047

AN - SCOPUS:85121444001

VL - 75

SP - 761

EP - 763

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -

Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this